About Vaxxas Vaxxas is a biotechnology company pioneering a needle-free vaccination technology designed to enhance immune response, reduce costs, and improve accessibility. The company recently ...

Geographic atrophy, an advanced form of dry age-related macular degeneration, leaves almost five million people around the ...

Brisbane-based ObvioHealth has signed a three-year agreement with clinical-stage biotechnology company Vaxxas to support late-stage trials.

Having examined the options trading patterns of Illumina, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance Trading volume ...

A wireless microchip implanted beneath the retina improved vision in 81% of patients with advanced age-related macular ...

Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that Dr. Peter Monteleone will present data from a sex-specific ...

Surmodics, Inc. , a leading provider of medical device and in vitro diagnostic technologies to the health care industry, today announced that results from a sex-specific analysis of 160 real-world ...

The annual meeting of the American Academy of Ophthalmology was held from Oct. 18 to 20 in Orlando, Florida, and attracted ...

A wireless photovoltaic implant shows promise in restoring central vision for patients with macular degeneration, enhancing visual acuity and independence.

In participants with geographic atrophy due to age-related macular degeneration, a photovoltaic retina implant microarray (PRIMA) system leads to significant improvement in visual acuity.

According to Nova One Advisor, the global genomics data analysis market size is calculated at USD 7.91 billion in 2025 and is ...